- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01099722
Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects at least 12 years old
- Female subjects less than 1 year post-menopausal must have a negative urine pregnancy test recorded at the screening visit prior to the first dose of study medication, be non-lactating, & willing to use adequate & highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently & correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner.
Known history of moderate to severe persistent, reversible asthma for ≥ 6 months prior to the Screening Visit characterised by:
Treatment with an inhaled corticosteroid (ICS) at a dose of 250 - 1000 µg fluticasone or equivalent OR Treatment wth ICS at a dose of 200-500 µg fluticasone or equivalent in combination with a Long Acting β2-Agonist (LABA).
Demonstrated a FEV1 of ≥ 50% to ≤ 80% for predicted normal values (Quanjer et al., 1993 (adults), & 1995 (adolescents)) during the Screening Period (Visit 1 or Visit 2) following appropriate withholding of asthma medications (if applicable).
- No β2-agonist use on day of testing
- No use of inhaled combination asthma therapy on day of testing.
- Inhaled corticosteroids are allowed on day of testing.
- Documented reversibility of ≥ 15% in FEV1 at visit 1 or visit 2.
- Demonstrated satisfactory technique in the use of the study medications i.e. pMDI and Dry Powder Inhaler (DPI) devices.
- Willing & able to enter information in the electronic diary & attend all study visits.
- Willing & able to substitute study medication for their pre study prescribed asthma medication for the duration of the study.
- Written informed consent obtained. Inclusion criteria required following run-in: Subject has used rescue medication for at least 3 days & had at least 1 night with sleep disturbance (i.e., sleep disturbance score of ≥ 1) during the last 7 days of the run in period,OR subject has used rescue medication for at least 3 days & had at least 3 days with asthma symptoms (i.e., a symptom score of ≥ 1) during the last 7 days of the run-in period.
Exclusion criteria:
- Near fatal or life-threatening (including intubation) asthma within the past year.
- Hospitalisation or an emergency visit for asthma within the 4 weeks before the Screening Visit.
- Known history of systemic (injectable or oral) corticosteroid medication use within 1 month of the Screening Visit.
- Known history of omalizumab use within the past 6 months.
- Current evidence or known history of any clinically significant disease or abnormality including uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia. 'Clinically significant' is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which would affect the outcome of the study.
- In the investigator's opinion a clinically significant upper or lower respiratory infection within 4 weeks prior to the Screening Visit.
- Significant, non-reversible, active pulmonary disease (e.g., chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, tuberculosis).
- Known Human Immunodeficiency Virus (HIV)-positive status.
- Subject has a smoking history equivalent to "10 pack years" (i.e., at least 1 pack of 20 cigarettes/day for 10 years or 10 packs/day for 1 year, etc.).
- Current smoking history within 12 months prior to the Screening Visit.
- Current evidence or known history of alcohol and/or substance abuse within 12 months prior to the Screening Visit.
- Subject has taken B-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrhythmics, or potent CYP 3A4 inhibitors such as ketoconazole within the past week.
- Current use of medications other than those allowed in the protocol that will have an effect on bronchospasm &/or pulmonary function.
- Current evidence or known history of hypersensitivity or idiosyncratic reaction to test medications or components.
- Subject has received an investigational drug within 30 days of the Screening Visit (12 weeks if an oral or injectable steroid).
- Subject is currently participating in a clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Inhaler
|
inhaler 2 puffs bd daily
2 puffs bd daily
|
Active Comparator: inhaler
Symbicort
|
2 puffs bd daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
non-inferiority in the efficacy of FlutiForm®
Time Frame: baseline to the end of the 12 week treatment
|
To show non-inferiority in the efficacy of FlutiForm® pMDI 125/5 µg (2 puffs bid) vs Symbicort® Turbohaler® 200/6 µg (2 puffs bid), based on the mean change in the pre morning dose value of forced expiratory volume in the first second (FEV1) from baseline (end of run-in period) to the end of the 12 week treatment period.
|
baseline to the end of the 12 week treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
---|---|
Additional efficacy and safety assessments
|
efficacy assessments include patient centered outcome assessments such as asthma quality of life questionnaire, subject's assessment of study medication, amount of rescue medication use, asthma symptom scores, sleep disturbance due to asthma, discontinuations due to lack of efficacy, compliance with study medication use & asthma exacerbations. Post dose FEV1, peak expiratory flow rates & other lung function parameters. Safety assessments include incidence & type of spontaneously reported adverse events, vital signs, laboratory tests and 12-lead ECGs. |
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FLT3507
- 2009-017223-25
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Universita di VeronaCompleted
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Flutiform
-
Mundipharma Korea LtdTerminated
-
Mundipharma Research LimitedCompleted
-
SkyePharma AGAbbottCompleted
-
Mundipharma Research LimitedCompletedChronic Obstructive Pulmonary DiseaseChina, Taiwan, Korea, Republic of, New Zealand, Australia
-
SkyePharma AGAbbottCompletedAsthmaUnited States, Ukraine, Mexico, Peru, Romania
-
Research in Real-Life LtdNapp Pharmaceuticals LimitedCompletedAsthmaUnited Kingdom
-
Mundipharma Research LimitedCompletedAsthma, BronchialHungary
-
SkyePharma AGAbbott; MDS Pharma ServicesCompletedAsthmaUnited States, Chile, Mexico, Peru, Romania, Hungary, South Africa, Ukraine, Poland, Argentina
-
SkyePharma AGCompleted
-
Mundipharma Research LimitedCompletedAsthmaRussian Federation, Ukraine, Bulgaria, Czechia, Hungary, India, Poland, Romania